NCT06142175View on ClinicalTrials.gov

Relmacabtagene Autoleucel in Patients With LBCL

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

December 28, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Large B-cell Lymphoma
Interventions
BIOLOGICAL

Relmacabtagene Autoleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,, Shanghai

All Listed Sponsors
lead

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY